Phone: +45 36 96 94 96 Mail: info@pentabase.com
  • Contact
  • FAQ
  • Distributors
  • Ressource
  • Product Catalogue
  • Book Test
  • Products
    • Assays
    • Instruments
  • Technology and services
    • Our proprietary technology
    • Custom Oligo
    • Baseblockers™
    • PentAdapters™
    • Fluorescent Probes
  • About Us
  • Services
    • SNP Genotyping Services
    • Real-Time PCR Assay Development
  • About
    • Meet the team
    • Career
    • News
    • Sponsorship
  • Services
  • Ordering
  • Support
  • Privacy Policy

Latest news

Friday 12. Aug 2022 by Aminat Makhauri

InfectionDetect-MPOX qPCR assay – A Danish developed qPCR assay for Monkeypox

Friday 29. Jul 2022 by Aminat Makhauri

MicroSight® MSI 1-step HRM Analysis for Microsatellite Instability

  • Contact
  • FAQ
  • Distributors
  • Ressource
  • Product Catalogue
Cart Cart

No products in the cart.

Menu

Press Release

12 August 2022
5 min

InfectionDetect-MPOX qPCR assay – A Danish developed qPCR assay for Monkeypox

Aminat Makhauri
Marketing & Communication Manager

PentaBase A/S, Danmark, August 12, 2022 – Since early May 2022, an increase in Monkeypox cases has been reported from non-endemic countries. The virus has spread from West and Central Africa to North America and Europe. Such a significant number of cases has never been reported before.

WHO is trying to prevent the further spread of the disease by guidance and increased surveillance. Once again, PentaBase has responded quickly to the new outbreak, and designed and produced a qPCR assay, specific and sensitive for the analysis of Monkeypox, validated on Monkeypox DNA extracted from Danish citizens by Rigshospitalet.

”PentaBase are proud that we once again, in close collaboration with the leading scientists in clinical microbiology from Rigshospitalet, can react swiftly to a need in society. Our newly developed research analysis, InfectionDetect™ - MPOX Virus qPCR Assay, which detects monkeypox virus-DNA, has now been confirmed to work on virus-DNA found in human samples in Denmark, by Rigshospitalet. ” says Ulf Bech Christensen, PentaBase A/S Chief Executive Director.

Two viral sequences, one internal control

InfectionDetect-MPOX qPCR assay from PentaBase is targeting two Monkeypox genome DNA sequences, J2R (HEX) and B7R (FAM), and the human RNAse P (Cy5) as a swabbing and amplification control.
The assay is for research use only. The two Monkeypox-specific regions have been validated in-silico against other orthopox viruses and have been found to be specific. The assay comprises positive and negative controls.

Validation

The analysis is developed on the BaseTyper™ real-time PCR instrument but will be validated on Bio-Rad’s CFX, Thermofishers’ Quant-Studio5 and Roche’s LightCycler480. Furthermore, the assay will be able to run on the fully automatic Cobas 6800 and 8800 in an open channel. The instrument time required for the analysis is 51 minutes when using a BaseTyper™.

For purification, we recommend the Viral RNA and DNA purification kit for the BasePurifier™, but other viral purification systems such as one from Biomerieux have also shown to work.

Sampling can be done using individual swabs for separate anatomic sites (rectal, oropharyngeal or skin lesions) added in individual transportation tubes comprising inactivating transport media (ITM) for the safety of downstream handling.

 

Contact PentaBase for more information at info@pentabase.com

Ready-To-Use (RTU) and Dispense Ready (DR)

The assay can be delivered as Ready-To-Use (RTU) or Dispense Ready (DR). In the RTU, we deliver pre-mixed assays in plastic chosen as the basis of your PCR machine. In the DR version, you mix the primer/probe mix and the mastermix into your own plastic tubes.

About PentaBase

We are a Danish, science based company which for more than 10 years have developed PCR-based products for scientists and medical professionals who explore new treatments and help patients worldwide. Our products are based on our own technology, Intercalating Nucleic Acid (INA®).

PentaBase is based in the heart of Denmark, Odense, and our science has been used to better the treatment planning of cancer patients worldwide. Luckily, we were able to utilize our science when the Corona pandemic hit Denmark, and we delivered approximately 50 % of the total number of PCR-tests in the first 6 months of the pandemic.

Sources: SSI, WHO 

 

 

    Sign up to our newsletter

    Receive information about new press release, marketing material and relevant PentaBase content.

    SHARE
    Share on facebook Share on linkedin Share on twitter

    Press Release

    Related
    " alt="thisisengineering-raeng-i7Irnuho8Xc-unsplash">

    July 29. 2022

    MicroSight® MSI 1-step HRM Analysis for Microsatellite Instability
    Covid-19 pcr analysis handling" alt="Covid-19 pcr analysis handling">

    May 16. 2022

    World’s first DNA methylation assay without pre-treatment
    PentaBase´s IVDR transition" alt="PentaBase´s IVDR transition">

    May 12. 2022

    PentaBase´s IVDR transition
    " alt="PentaBase and TDF Icon on top">

    March 22. 2022

    PentaBase gears up and joins Tour de France!
    hounö logo
    facebook linkedin twitter

    About

    • About Us
    • Meet the team
    • News
    • Career
    • Sponsorships

    Covid-19

    • Book Test
    • COVID-19 for Companies

    Assays & Instruments

    • Cancer Stratification and Monitoring
    • CoviDetect™ Variants Assay
    • CoviDetect™ FAST Assay
    • CoviDetect™ Assay
    • Oligonucleotides
    © Copyright 2023 Pentabase A/S CVR: 30197852 Petersmindevej 1A DK-5000 Odense C, Denmark
    • Privacy Policy
    • Terms of payment
    • Cookie Policy